中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.022 seconds)

    2.
    发明专利
    未知

    公开(公告)号：FR2827288A1

    公开(公告)日：2003-01-17

    申请号：FR0109260

    申请日：2001-07-12

    Applicant: SERVIER LAB

    Inventor： GOLDSTEIN SOLO ,  POISSONNET GUILLAUME ,  PARMENTIER JEAN GILLES ,  LESTAGE PIERRE ,  LOCKHART BRIAN

    IPC: A61K31/4985 ,  A61K31/5025 ,  A61P3/04 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/28 ,  A61P43/00 ,  C07D221/00 ,  C07D241/00 ,  C07D471/04

    Abstract: Octahydro-2H-pyrido(1,2-a) pyrazine derivatives (I), their enantiomers, diastereoisomers, and salts with acids and bases are new. Octahydro-2H-pyrido(1,2-a) pyrazine derivatives of formula (I), their enantiomers, diastereoisomers, and salts with acids and bases are new. Ra = 1-6C alkylene chain; Y = aryl, heteroaryl, or a fused bicyclic ring of formula (a); W1 and W2 = O, S, or NR2; R2 = H, 1-6C alkyl or acyl, aryl, or arylalkyl; R1 = H or 1-6C alkyl; A = a 4-7 membered N heterocycle which is unsaturated or partially saturated (optionally containing a second hetero atom (O, N or S) and optionally substituted by oxo, or 1-6C alkyl); and B = phenyl (optionally substituted by one or more groups selected from halogens, nitro, CN, OH, 1-6C (alkoxy, alkyl, trihaloalkyl, acyl, acyloxy, alkoxycarbonyl or alkylsulfanyl), sulfanyl or amino (optionally substituted by one or two 1-6C alkyl, aryl and 1-6C arylalkyl groups). Provided that: (1) when Y is aryl or heteroaryl, then X is W1, -C(W1)-W2-, -W2-C(W1)-, -W2-C(W1)W2-, -W2-Ra, or -CH(OR1); (2) when Y is a fused bicyclic ring, then X is a simple bond, -C(W1)-, -W2-C(W1)-, -W2-Ra, or -CH(OR1); and (3) compounds 2-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl-1-phenyl ethanol;3-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl propyl-3,4,5-trimethoxy benzoate; and 2-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl ethyl-3,4,5-trimethoxy benzoate are excluded.

    9.
    发明专利
    未知

    公开(公告)号：FR2867780B1

    公开(公告)日：2006-05-19

    申请号：FR0402841

    申请日：2004-03-19

    Applicant: SERVIER LAB

    Inventor： DE NANTEUIL GUILLAUME ,  GLOANEC PHILIPPE ,  PARMENTIER JEAN GILLES ,  BENOIST ALAIN ,  RUPIN ALAIN ,  VALLEZ MARIE ODILE ,  VERBEUREN TONY

    IPC: C07D487/04 ,  A61K31/4985 ,  A61K31/519 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P43/00 ,  C07D207/12 ,  C07D241/08

    Abstract: 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds (I) are new. 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds of formula (I) are new. A : 1-oxidopyridyl substituted by the remainder of the molecule in any one of the positions 2, 3 and 4; m, n : 1 - 3; R 1H or linear or branched (1-6C)alkyl; R 2, R 3hydrogen, halogen, linear or branched (1-6C)alkyl, hydroxy, linear or branched (1-6C)acyloxy or linear or branched (1-6C)alkoxy; R 2+R 33-6C cycloalkane; R 4, R 5H; R 4+R 5benzo ring; Ar : phenyl, biphenylyl or naphthyl (optionally substituted by at least one of T 1) or 5 - 12-membered mono- or bi-cyclic aromatic group (containing 1 - 3 heteroatoms selected from O, N or S; and optionally substituted by at least one of T 1); and T 1halo, linear or branched (1-6C)alkyl (optionally substituted by hydroxy, carboxy or carbamoyl (optionally mono- or di-substituted by linear or branched (1-6C)alkyl, linear or branched (1-6C)alkoxy, hydroxy, trihalo-(1-6C)alkyl (in which the alkyl moiety is linear or branched), amino (optionally mono- or di-substituted by linear or branched (1-6C)alkyl, carboxymethoxy or carbamoylmethoxy (optionally mono- or di-N-substituted by linear or branched (1-6C)alkyl, hydroxy-(1-6C)alkyl (in which the alkyl moiety is linear or branched), alkoxyalkyl (in which the alkoxy and alkyl moieties are each linear or branched 1-6C) or pyridylalkyl (in which the alkyl moiety is linear or branched 1-6C)))). The configuration of the asymmetric centre at the alpha position with respect to the amide is (S). [Image] ACTIVITY : Antianginal; Thrombolytic; Cardiant; Vasotropic; Cardiovascular-Gen.; Antiarteriosclerotic. MECHANISM OF ACTION : Thrombin inhibitors. The inhibitory activity of 3-{[2,2-difluoro-2-(1-oxido-2-pyridyl)ethyl]amino}-4-oxo-N-[2-(2-oxo-2-{[2-(2-pyridyl)ethyl]amino}ethoxy)benzyl]-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide hydrochloride (A) was evaluated on human thrombin. The purified human fibrinogen (4 mM) was added to thrombin (0.7 nM) that had previously been incubated optionally with the inhibitor to be tested (20[deg]C, 10 minutes). Inhibitors, enzymes and substrates were diluted in the same buffer (0.01 mM phosphate buffer, pH 7.4, containing sodium chloride (0.12 M) and bovine serum albumin (0.05%)) and then distributed on a polystyrene microtitre plate in a volume of 50 mu l. The fibrin formed by the thrombin was measured using a spectrophotometer at 405 nm after 10 - 15 minutes reaction at 20[deg]C. The IC 50 value of (A) was found to be 1.4 nM.

    10.
    发明专利
    未知

    公开(公告)号：FR2867780A1

    公开(公告)日：2005-09-23

    申请号：FR0402841

    申请日：2004-03-19

    Applicant: SERVIER LAB

    Inventor： DE NANTEUIL GUILLAUME ,  GLOANEC PHILIPPE ,  PARMENTIER JEAN GILLES ,  BENOIST ALAIN ,  RUPIN ALAIN ,  VALLEZ MARIE ODILE ,  VERBEUREN TONY

    IPC: A61K31/519 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P43/00 ,  C07D487/04 ,  A61K31/4985

    Abstract: 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds (I) are new. 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds of formula (I) are new. A : 1-oxidopyridyl substituted by the remainder of the molecule in any one of the positions 2, 3 and 4; m, n : 1 - 3; R 1H or linear or branched (1-6C)alkyl; R 2, R 3hydrogen, halogen, linear or branched (1-6C)alkyl, hydroxy, linear or branched (1-6C)acyloxy or linear or branched (1-6C)alkoxy; R 2+R 33-6C cycloalkane; R 4, R 5H; R 4+R 5benzo ring; Ar : phenyl, biphenylyl or naphthyl (optionally substituted by at least one of T 1) or 5 - 12-membered mono- or bi-cyclic aromatic group (containing 1 - 3 heteroatoms selected from O, N or S; and optionally substituted by at least one of T 1); and T 1halo, linear or branched (1-6C)alkyl (optionally substituted by hydroxy, carboxy or carbamoyl (optionally mono- or di-substituted by linear or branched (1-6C)alkyl, linear or branched (1-6C)alkoxy, hydroxy, trihalo-(1-6C)alkyl (in which the alkyl moiety is linear or branched), amino (optionally mono- or di-substituted by linear or branched (1-6C)alkyl, carboxymethoxy or carbamoylmethoxy (optionally mono- or di-N-substituted by linear or branched (1-6C)alkyl, hydroxy-(1-6C)alkyl (in which the alkyl moiety is linear or branched), alkoxyalkyl (in which the alkoxy and alkyl moieties are each linear or branched 1-6C) or pyridylalkyl (in which the alkyl moiety is linear or branched 1-6C)))). The configuration of the asymmetric centre at the alpha position with respect to the amide is (S). [Image] ACTIVITY : Antianginal; Thrombolytic; Cardiant; Vasotropic; Cardiovascular-Gen.; Antiarteriosclerotic. MECHANISM OF ACTION : Thrombin inhibitors. The inhibitory activity of 3-{[2,2-difluoro-2-(1-oxido-2-pyridyl)ethyl]amino}-4-oxo-N-[2-(2-oxo-2-{[2-(2-pyridyl)ethyl]amino}ethoxy)benzyl]-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide hydrochloride (A) was evaluated on human thrombin. The purified human fibrinogen (4 mM) was added to thrombin (0.7 nM) that had previously been incubated optionally with the inhibitor to be tested (20[deg]C, 10 minutes). Inhibitors, enzymes and substrates were diluted in the same buffer (0.01 mM phosphate buffer, pH 7.4, containing sodium chloride (0.12 M) and bovine serum albumin (0.05%)) and then distributed on a polystyrene microtitre plate in a volume of 50 mu l. The fibrin formed by the thrombin was measured using a spectrophotometer at 405 nm after 10 - 15 minutes reaction at 20[deg]C. The IC 50 value of (A) was found to be 1.4 nM.

Patent Agency Ranking